Preview

Pediatric pharmacology

Advanced search

Hunter Syndrome: Clinical Case of Early Diagnostics

https://doi.org/10.15690/pf.v17i5.2185

Abstract

Background. This clinical case of orphan disease can be interesting for its early diagnostics which is essential for timely specific therapy and sufficient dynamic observation. Clinical case description. Mucopolysaccharidosis type II (Hunter syndrome) diagnosis at the age of 12 months was based on common external manifestations, recurrent otitis and isolated osteoarticular system lesions without any other systems decompensations. The awareness of doctors about the disease criteria and its diagnostics algorithm, as well as the availability of laboratory testing on lysosomal enzyme iduronate-2-sulfatase (I2S) activity are crucial for early diagnosis. The patient has undergone molecular genetic testing: mutations in the IDS gene encoding iduronate-2-sulfatase were revealed. The enzyme replacement therapy with idursulfase according to the protocol has been started. Patient’s condition has improved on the therapy (after 4 months of the therapy): stable neuropsychic development (no delay), increased large joints flexibility, reduced hepatosplenomegaly, and no hearing loss. Conclusion. Timely diagnostics of mucopolysaccharidosis allows to start enzyme replacement therapy early and significantly ease the disease course despite the severe congenital defect in the glycosaminoglycans metabolism.

About the Authors

Natalya N. Martynovich
Irkutsk State Medical University
Russian Federation
Irkutsk
Disclosure of interest: Not declared.


Yulia P. Semshchikova
Irkutsk State Medical University
Russian Federation
Irkutsk
Disclosure of interest: Not declared.


Natalya Yu. Rudenko
Irkutsk State Regional Children's Clinical Hospital
Russian Federation
Irkutsk
Disclosure of interest: Not declared.


Vera M. Shinkareva
Irkutsk State Regional Children's Clinical Hospital
Russian Federation
Irkutsk
Disclosure of interest: Not declared.


Kristina V. Egorycheva
Irkutsk State Regional Children's Clinical Hospital
Russian Federation
Irkutsk
Disclosure of interest: Not declared.


References

1. Atlas redkikh boleznei. Baranov AA, Namazova-Baranova LS, eds. 2nd augmented ed. — Moscow: Pediatr; 2016. — 420 p. (In Russ).

2. Martynovich NN, Barzunova TV, Semschikova YuP. Experience of practical training of future pediatricians in academic discipline of choice “Orfan diseases”. Pacific Medical Journal. 2020;(1(79)):85–87. (In Russ). doi: 10.34215/1609-1175-2020-1-85-87.

3. Martin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008;121(2):377–386. doi: 10.1542/peds.2007-1350.

4. Thappa DM, Singh A, Jaisankar TJ, et al. Pebbling of the Skin: A Marker of Hunter’s Syndrome. Pediatr Dermatol.1998;15(5):370–373. doi: 10.1046/j.1525-1470.1998.1998015370.x.


Review

For citations:


Martynovich N.N., Semshchikova Yu.P., Rudenko N.Yu., Shinkareva V.M., Egorycheva K.V. Hunter Syndrome: Clinical Case of Early Diagnostics. Pediatric pharmacology. 2020;17(5):455-458. (In Russ.) https://doi.org/10.15690/pf.v17i5.2185

Views: 3703


ISSN 1727-5776 (Print)
ISSN 2500-3089 (Online)